C07C 255/60
At least one of the singly-bound nitrogen atoms being acylated
Official title: at least one of the singly-bound nitrogen atoms being acylated
C07C255/60 (At least one of the singly-bound nitrogen atoms being acylated) appears on 341 US grants and 394 published applications in this corpus.
Search patents in C07C- Granted patents
- 341
- Published applications
- 394
- Assignees
- 229
- Inventors
- 1,284
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 7 | 0 |
| 1997 | 8 | 0 |
| 1998 | 7 | 0 |
| 1999 | 8 | 0 |
| 2000 | 10 | 0 |
| 2001 | 10 | 1 |
| 2002 | 9 | 8 |
| 2003 | 8 | 20 |
| 2004 | 4 | 27 |
| 2005 | 9 | 18 |
| 2006 | 11 | 21 |
| 2007 | 12 | 20 |
| 2008 | 12 | 21 |
| 2009 | 11 | 25 |
| 2010 | 21 | 19 |
| 2011 | 13 | 13 |
| 2012 | 12 | 17 |
| 2013 | 14 | 16 |
| 2014 | 20 | 14 |
| 2015 | 14 | 15 |
| 2016 | 11 | 15 |
| 2017 | 14 | 19 |
| 2018 | 14 | 13 |
| 2019 | 8 | 11 |
| 2020 | 11 | 18 |
| 2021 | 8 | 15 |
| 2022 | 6 | 11 |
| 2023 | 11 | 11 |
| 2024 | 9 | 14 |
| 2025 | 7 | 10 |
| 2026 | 3 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Heterocyclic compounds as antagonist of NMDA26 May 2026US 12,637,418 B2Takeda Pharmaceutical Company Limited
- Intestine-specific partial agonists of farnesoid X receptor and uses thereof13 Jan 2026US 12,522,562 B2EWHA DrugDesignHouse Co.,Ltd.
- GPX4 inhibitors, pharmaceutical compositions thereof, and their use for treating GPX4-mediated diseases6 Jan 2026US 12,516,016 B2Eubulus Biotherapeutics (Hong Kong) Limited
- Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof23 Dec 2025US 12,503,426 B2Lipovexa Srl
- Tricyclic spiro compound16 Dec 2025US 12,497,377 B2Ono Pharmaceutical Co., Ltd.
- Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-lpi) and uses thereof16 Jul 2026US 2026/0200837 A1Lipovexa Srl
- Masp-2 inhibitors and methods of use9 Jul 2026US 2026/0193179 A9Omeros Corporation
- Masp-2 inhibitors and methods of use11 Dec 2025US 2025/0376443 A1Omeros Corporation
- Masp-2 inhibitors and methods of use4 Dec 2025US 2025/0368604 A1Omeros Corporation
- Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto27 Nov 2025US 2025/0359552 A1Corteva Agriscience LLC
Most cited
By later US patents
- Benzamides and related inhibitors of factor Xa115US 6,376,515 B2COR Therapeutics, Inc. · 2002
- Potent inducers of terminal differentiation and methods of use thereof95US 5,369,108 ASloan-Kettering Institute for Cancer Research · 1994
- Potent inducers of terminal differentiation and methods of use thereof91US 6,087,367 ASloan-Kettering Institute for Cancer Research · 2000
- Potent inducers of terminal differentiation and method of use thereof89US 5,700,811 ASloan-Kettering Institute for Cancer Research · 1997
- Cyano containing oxamic acids and derivatives as thyroid receptor ligands84US 6,194,454 B1Pfizer Inc. · 2001